Ayala Pharmaceuticals Inc (ADXS)

[dafreaks]

Bourbon, I posted those bullet points on Facebook, Noelle responded:

Good afternoon. Please feel free to call me if you would like to discuss any of these items in more detail; my number is 609-250-7575. I will respond to the original comment because there are a number of misunderstandings within it. I will go through the items one by one; each numeral corresponds with each bullet point. 1. We are committed to commercialization, and the EMA MAA is part of this plan. 2. Back in November at the Jefferies HCC, we announced that the EU filing would now take place in Q1 of 2018 because of additional information that we had been advised to obtain. We are on track to submit in Q1 of 2018. 3. We will provide an AIM2CERV update midyear, as planned. 4. Astra combo - This is ongoing, with a milestone achieved in late 2017 and interim readout planned for 2019 and on track. 5. BMS combo - On track for H1 2018. 6. An IST is on track and will be announced in H1 2018. 7. After encouraging data presented in the fall, we are on track for combo data to be presented in 2018. 8. This is preclinical and is ongoing. 9. NEO is on track to hit 2018 milestones. 10. See number 9. 11. HOT is on track to hit 2018 milestones. 12. See number 11. Regarding fiscal discipline, I would encourage you to listen to our 2017 YE call from December 21st, wherein Sara our CFO discusses the reduction in burn rate. Again, please call if you have additional questions, just wanted to provide some clarification on this post.